ANGO Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -7.99% compared to AngioDynamics, Inc.'s net margin of -12425.36%. AngioDynamics, Inc.'s return on equity of -15.21% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

AngioDynamics, Inc. has a consensus price target of $19.33, signalling upside risk potential of 85.54%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.4167 which suggests that it could grow by 145.39%. Given that Perspective Therapeutics, Inc. has higher upside potential than AngioDynamics, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than AngioDynamics, Inc..

AngioDynamics, Inc. has a beta of 0.514, which suggesting that the stock is 48.595% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.747, suggesting its more volatile than the S&P 500 by 74.695%.

AngioDynamics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

AngioDynamics, Inc. quarterly revenues are $79.4M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. AngioDynamics, Inc.'s net income of -$6.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, AngioDynamics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics, Inc. is 1.39x versus 343.09x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystem Holdings, Inc. has a net margin of -7.99% compared to AngioDynamics, Inc.'s net margin of 6.19%. AngioDynamics, Inc.'s return on equity of -15.21% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

AngioDynamics, Inc. has a consensus price target of $19.33, signalling upside risk potential of 85.54%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 72.33%. Given that AngioDynamics, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe AngioDynamics, Inc. is more attractive than InfuSystem Holdings, Inc..

AngioDynamics, Inc. has a beta of 0.514, which suggesting that the stock is 48.595% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.674, suggesting its more volatile than the S&P 500 by 67.352%.

AngioDynamics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

AngioDynamics, Inc. quarterly revenues are $79.4M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. AngioDynamics, Inc.'s net income of -$6.4M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, AngioDynamics, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 31.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics, Inc. is 1.39x versus 1.24x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -7.99% compared to AngioDynamics, Inc.'s net margin of -862.39%. AngioDynamics, Inc.'s return on equity of -15.21% beat VolitionRX Ltd.'s return on equity of --.

AngioDynamics, Inc. has a consensus price target of $19.33, signalling upside risk potential of 85.54%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 731.76%. Given that VolitionRX Ltd. has higher upside potential than AngioDynamics, Inc., analysts believe VolitionRX Ltd. is more attractive than AngioDynamics, Inc..

AngioDynamics, Inc. has a beta of 0.514, which suggesting that the stock is 48.595% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.286, suggesting its more volatile than the S&P 500 by 28.569%.

AngioDynamics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

AngioDynamics, Inc. quarterly revenues are $79.4M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. AngioDynamics, Inc.'s net income of -$6.4M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, AngioDynamics, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics, Inc. is 1.39x versus 18.12x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -7.99% compared to AngioDynamics, Inc.'s net margin of 3.93%. AngioDynamics, Inc.'s return on equity of -15.21% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

AngioDynamics, Inc. has a consensus price target of $19.33, signalling upside risk potential of 85.54%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 149.58%. Given that Xtant Medical Holdings, Inc. has higher upside potential than AngioDynamics, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than AngioDynamics, Inc..

AngioDynamics, Inc. has a beta of 0.514, which suggesting that the stock is 48.595% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.041, suggesting its less volatile than the S&P 500 by 104.125%.

AngioDynamics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

AngioDynamics, Inc. quarterly revenues are $79.4M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. AngioDynamics, Inc.'s net income of -$6.4M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, AngioDynamics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 58.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics, Inc. is 1.39x versus 0.66x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.